New Delhi: Leading pharmaceutical company Cipla has sought permission to launch Favipiravir, an anti-viral drug, in India to fight against COVID-19.
Sources said the Council of Scientific and Industrial Research (CSIR) had developed an affordable process by using locally available chemicals to synthesise this Active Pharmaceutical Ingredient (API) and then transferred the technology to Cipla for mass production.
Favipiravir has shown promise in clinical trials for treatment of mild and moderate cases of COVID-19 patients, according to a statement by Cipla.
“Cipla has scaled up the process in its manufacturing facility and approached the Drug Controller General of India (DCGI) for permission to launch the product in India. Given that DCGI has given restricted emergency use for Favipiravir in the country, Cipla is now all set to launch the product to help COVID-19 patients,” the statement added.
CSIR Director General Shekhar C Mande said they are working with the industry in developing quick solutions and products for mitigation of COVID-19.
COVID Fight: Drug Watchdog Okays Favipiravir For Clinical Trials In India
Bhubaneswar: Prime Minister Narendra Modi will campaign for BJP ahead of the first-round of elections…
Bhubaneswar: The Congress has nominated Biswabhusan Das, who had returned to the party from BJP…
New Delhi: A man in Bihar married his mother-in-law after the family after he had…
Bhubaneswar: The Railway Protection Force (RPF) seized more than 100 turtles while being transported in…
Berhampur: In order to help the college and university teachers in their research activities in…
New Delhi: The Congress party on Tuesday released another list of candidates for the ongoing…
New Delhi: A former Miss Ecuador contestant was shot and killed by two gunmen in…
Bhubaneswar: Another former MLA of BJD in Odisha resigned from the party on Tuesday after…